Related Experiment Video

Updated: Aug 21, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumolysin in the immunopathogenesis and treatment of pneumococcal disease

Riana Cockeran1, Ronald Anderson, Charles Feldman

  • 1University of Pretoria, Pretoria, South Africa. rcockera@medic.up.ac.za.

Expert Review of Anti-Infective Therapy
|October 16, 2004
PubMed

Insights

Pneumolysin is a key factor in pneumococcal infections, contributing to disease spread and inflammation. This protein is a target for new vaccines and treatments like macrolides and corticosteroids.

Area of Science:

  • Immunology
  • Microbiology
  • Pharmacology

Background:

  • Pneumococcal infections cause significant illness and death.
  • Pneumolysin is a major virulence factor in pneumococcal pathogenesis.
  • It plays roles in colonization, invasion, dissemination, and inflammation.

Purpose of the Study:

  • To highlight pneumolysin's role in pneumococcal infection.
  • To discuss its potential as a vaccine carrier protein.
  • To explore pharmacological strategies targeting pneumolysin.

Main Methods:

  • Review of recent insights into pneumococcal immunopathogenesis.
  • Analysis of pneumolysin's function as a virulence factor.
  • Evaluation of pneumolysin-directed therapeutic approaches.

Main Results:

  • Pneumolysin is implicated in microbial colonization, invasion, dissemination, and tissue inflammation.
  • It is a highly immunogenic polypeptide found in all clinically relevant pneumococcal isolates.
  • Pneumolysin is a potential carrier protein for conjugate vaccines.

Conclusions:

  • Pneumolysin is a critical target for understanding and combating pneumococcal infections.
  • Pharmacological strategies, including macrolides and corticosteroids, show promise for acute disease treatment.
  • Pneumolysin's immunogenicity makes it a valuable component for vaccine development.

More Related Videos

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: